Space missions don’t launch without simulations. Clinical trials shouldn’t either.
We create simulations that capture disease biology to move your pipeline forward, with confidence. Know the efficacy and safety profile of your drug before facing late-stage failures.
The translational platform that gets your drug to market faster.
Determine target efficacy in seconds.
BioTarget™ Scoring Tool
Disease models to predict target efficacy.
Omic Signatures™
Identify predictive biomarkers to predict patient responders.
Data Exploration Tool
Versatile data visualization suite to transform complex data into actionable biological insights.
The only no-code, high-fidelity SaaS platform for efficacy simulation.
BioTarget™ Scoring Tool
Accurate models to trace disease pathways and understand mechanisms of action.
Calculate the efficacy of your target or combination of targets.
Insights to drive key decisions during drug development.
Predict new molecular interactions previously unknown.
Prioritize drug targets in your pipeline and compare to targets in the competitive landscape.
Omic Signatures™
Identify biomarkers indicative of disease progression, drug efficacy and resistance.
Identify combinations of biomarkers more predictive of drug response than single biomarkers.
Accurately stratify patients to find the right subgroups to meet Phase II/III endpoints, the first time.
Pathway contextualization of differentially-expressed genes or proteins .
Easy to use, upload data and have results in seconds.
Data Exploration Tool
Upload, download, customize in seconds.
Intuitive display of data analyses to maximize insights.
Easy data pre-processing, analysis and visualization.
One platform for every stage of drug development.
Why companies choose Simmunome.
Choosing Simmunome's platform enables clients to harness the power of precision medicine, data integration, and advanced analytics, ultimately leading to improved patient outcomes and accelerated research discoveries.
AI Models
AI models boost our algorithm’s capabilities by augmenting the biological knowledge available.
Secured Access
No one can access the network unless they are authenticated. We rely on Auth0 and JWTs to ensure online safety.
Custom Data Integration
Models safely leverage your own custom data to get results targeted for your specific needs.
No-Code
Plug and play platform providing reliable insights without the need for any AI expertise.
Unified, actionable insights that drive clinical research forward.
Hybrid Approach.
Our unique approach combines mechanistic modeling and machine learning algorithms. Abiding by biological rules, it surpasses traditional methods and pure data-driven approaches in reliability.
Traceable Predictions.
Enabling clients to trace results to every interaction that influences calculated efficacy or safety profiles.
Speed & Flexibility.
Development of disease models across different therapeutic areas, allowing for comparisons across diseases and swift pivoting to indications with greatest potential.
+20,000
Patient samples integrated.
+1.3M
Dynamic molecular interactions.
9
Pre-built disease models, ready to go.
7x
Our predictive tools reduce the probability of failure by.
$1.4B
Potential savings, per successful drug.
Ways to work with Simmunome.
Whether it’s a turn-key solution for autonomous analysis or a customized approach, Simmunome is there to provide fast, accurate results to make key go/no-go decisions about your pipeline.
Service
White-glove service for customized solutions.
SaaS
Customer-led upload for autonomous decision making.
Library of Disease Models
-
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Melanoma
-
Alzheimer’s Disease
Parkinson’s Disease
ALS
-
Tissue Repair
Don’t see your therapeutic area here? Simmunome can develop disease models for your specific indication. Check in regularly with us to see our growing library.
BioTarget™ Scoring Tool - the only tool to predict efficacy before initiating a clinical trial.
Gone are the days of predicting efficacy by drug class.
Simmunome’s BioTarget™ Scoring Tool predicts the efficacy response of inhibiting, or activating, a target by tracing the biological pathways leading to disease endpoints. We simulated disease pathways and used the protein geometric structure to calculate an efficacy score and range. Efficacy scores were compared to the observed efficacy response ranges of previously completed clinical trials – successful or not – to see how we measured up.
HER2 in Advanced Breast Cancer
Target: Human Epidermal Growth Factor Receptor 2 (HER2)
Disease: Advanced Breast Cancer
Approved Drugs: Trastuzumab
BioTarget™ Prediction: 44-67%
Observed Overall Response Rate (Ref 1): 58%
Disappointed by the poor predicted efficacy for your target?
BioTarget™ will find combinations of targets that are highly effective and surpass current standard of care.
Why is BioTarget™ superior to current methods?
This is the only too to provide both quantitative & qualitative explanations of disease pathways that are, or are not, addressed by activating or inhibiting a drug target.
BACE1 in Alzheimer’s Disease
Target: β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)
Disease: Alzheimer’s Disease
Approved Drugs: No approved BACE1 drugs and several others terminated due to lack of efficacy.
BioTarget™ Prediction: 0%
Observed Response Rate (Ref 2): None of the disease pathways targeting BACE1 lead to the disease endpoints. BioTarget™ clearly demonstrates BACE1 is not an effective as a drug target.
References
You Asked, We Answered
We put together this FAQ video to answer some of the most commonly asked questions about our technology.
🔍 Interested in learning about how AI can make drug development more efficient?
🧬 Curious about what type of clinical data is required?
🔬 Wondering when is the best time to integrate AI in your drug development process?
Simmunome believes in the responsible development of AI to benefit humanity.
Simmunome’s members are trained in the TRAIL program. The training program was initiated and designed under the supervision of Yoshua Bengio, Scientific Director at Mila. The program is aimed at teaching AI researchers to implement ethical, legal and governance considerations in their methodology and practices.
De-risk your clinical development pipeline.
Simmunome dramatically increases your probability of success to get you to market faster, and reduce your R&D costs.